Trials of prostate-cancer screening are not worthwhile

The Lancet Oncology

Volumn 10, Issue 3, 2009, Pages 294-298

  Dubben, Hans Hermann ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CAUSE OF DEATH; CLINICAL STUDY; CLINICAL TRIAL; DEVELOPED COUNTRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; SAMPLING; SENSITIVITY AND SPECIFICITY; MORTALITY; PATIENT COMPLIANCE; PROSTATE TUMOR; SAMPLE SIZE;

CAUSE OF DEATH; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PATIENT COMPLIANCE; PROSTATIC NEOPLASMS; SAMPLE SIZE;

EID: 62849118351     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70066-X     Document Type: Note

References (32)

1. Parkin D., Bray F., and Devesa S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37 (2001) 4-66
2. Sakr W.A., Grignon W.J., Haas G.P., Heilbrun L.K., Pontes J.E., and Crissman J.D. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 30 (1996) 138-144
3. Surveillance Epidemiology and End Results (SEER). Cancer statistics review 1975-2004 (2006). http://srab.cancer.gov/devcan/ (accessed Oct 2, 2007).
4. Federal Statistical Office (Germany). [Causes of death in Germany in 2005 (2007), Federal Statistical Office, Wiesbaden Article number 2120400057004.] (In German).
5. Fossa S.D., Eri L.M., Skovlund E., Tveter K., and Vatten L. No randomised trial of prostate-cancer screening in Norway. Lancet Oncol 2 (2001) 741-745
6. Ilic D., O'Connor D., Green S., and Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev 3 (2006) CD004720.
7. Rohde V., Katalinic A., and Wasem J. Diseases of the prostate-Health report of the federal government 2007 (2007), Robert Koch-Institut, Berlin (in German).
8. Quinn M., and Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality, part I: international comparisons. BJU International 90 (2002) 162-173
9. De Koning H.J., Auvinen A., Berenguer-Sanchez A., et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 97 (2002) 237-244
10. Labrie F., Candas B., Cusan L., et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59 (2004) 311-318
11. Sandblom G., Varenhorst E., Lofman O., Rosell J., and Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 46 (2004) 717-724
12. Attems J., Arbes S., Böhm G., Böhmer F., and Lintner F. The clinical diagnostic accuracy rate regarding the immediate cause of death in a hospitalized geriatric population; an autopsy study of 1594 patients. Wien Med Wochenschr 154 (2004) 159-162
13. Hopker W.W., and Burkhardt H.U. Nonsense and sense in cause-of-death statistics. A validation study to test cancer mortality figures. Dtsch Med Wochenschr 109 (1984) 1269-1274
14. De Koning H.J., Blom J., Merkelbach J.W., et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU International 92 suppl 2 (2003) 71-78
15. De Koning H.J., Liem M.K., Baan C.A., Boer R., Schröder F.H., and Alexander F.E. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 98 (2002) 268-273
16. Lujan M., Paez A., Pascual C., and Angulo J. Extent of prostate-specific antigen contamination in the Spanish section of the European randomized study of screening for prostate cancer (ERSPC). Eur Urol 50 (2006) 1234-1240
17. Zelen M. Statistical issues in the planning of prevention studies. Cancer Invest 6 (1988) 615-620
18. Zelen M. Are primary cancer prevention trials feasible?. J Natl Cancer Inst 80 (1988) 1442-1444
19. Smith D.P., and Armstrong B.K. Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust 169 (1998) 17-20
20. Russo A., Autelitano M., Bellini A., and Bisanti L. Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy. J Med Screen 9 (2002) 179-180
21. Bangma C.H., Roemeling S., and Schröder F.H. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25 (2007) 3-9
22. Ciatto S., Gervasi G., Bonardi R., et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 41 (2005) 411-415
23. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
24. Schilling F.H., Spix C., Berthold F., et al. Neuroblastoma screening at one year of age. N Engl J Med 346 (2002) 1047-1053
25. Black W.C., Haggstrom D.A., and Welch H.G. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94 (2002) 167-173
26. Farwell W.R., Linder J.A., and Jha A.K. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 167 (2007) 2497-2502
27. Beck-Bornholdt H.P., and Dubben H.H. Is the pope an alien?. Nature 381 (1996) 730
28. Beck-Bornholdt H.P., and Dubben H.H. The philosopher's shine-fallacies and misjudgement in daily thinking (2003), Rowohlt Verlag, Hamburg (in German).
29. Dubben H.H., and Beck-Bornholdt H.P. The meaning of statistical significance. In: Diekmann A. (Ed). Methods of social research (2006), VS-Publisher of Social Science, Wiesbaden (in German).
30. Ioannidis J. Why most published research findings are false. PLoS Med 2 (2005) 124
31. Sterne J., and Smith G.D. Sifting the evidence-what's wrong with significance tests?. BMJ 322 (2001) 226-231
32. Zelen M. Theory and practice of clinical trials. In: Bast R.C., Pollock R.E., Kufe D.W., Weichselbaum R.R., and Frei E. (Eds). Cancer Medicine (2000), B C Decker, Hamilton